200 related articles for article (PubMed ID: 12468399)
1. Antibody-based therapy of non-Hodgkin's lymphoma.
Foran JM
Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
[TBL] [Abstract][Full Text] [Related]
2. [Proteins in haematology].
Clarenbach RE; Mey U
Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
4. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
5. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab.
Fietz T; Thiel E
Recent Results Cancer Res; 2007; 176():153-63. PubMed ID: 17607923
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy in lymphoid malignancies.
Hainsworth JD
Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.
Kahl B
Semin Hematol; 2008 Apr; 45(2):90-4. PubMed ID: 18381103
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
9. Antibody therapy of lymphoma.
Illidge TM; Bayne MC
Expert Opin Pharmacother; 2001 Jun; 2(6):953-61. PubMed ID: 11585011
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibodies in hematology in 2009].
Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
[TBL] [Abstract][Full Text] [Related]
12. Hematologic malignancies: new developments and future treatments.
Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
[TBL] [Abstract][Full Text] [Related]
13. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
14. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
16. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
Łuczyński W; Krawczuk-Rybak M
Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
19. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
20. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
